@article{6f891e638a354139b0daae19c4040e9b,
title = "The histone methyltransferase SETD2 negatively regulates cell size",
abstract = "Cell size varies between cell types but is tightly regulated by cell intrinsic and extrinsic mechanisms. Cell size control is important for cell function, and changes in cell size are frequently observed in cancer. Here, we uncover a role for SETD2 in regulating cell size. SETD2 is a lysine methyltransferase and a tumor suppressor protein involved in transcription, RNA processing and DNA repair. At the molecular level, SETD2 is best known for associating with RNA polymerase II through its Set2-Rbp1 interacting (SRI) domain and methylating histone H3 on lysine 36 (H3K36) during transcription. Using multiple independent perturbation strategies, we identify SETD2 as a negative regulator of global protein synthesis rates and cell size. We provide evidence that overexpression of the H3K36 demethylase KDM4A or the oncohistone H3.3K36M also increase cell size. In addition, ectopic overexpression of a decoy SRI domain increased cell size, suggesting that the relevant substrate is engaged by SETD2 via its SRI domain. These data add a central role of SETD2 in regulating cellular physiology and warrant further studies on separating the different functions of SETD2 in cancer development.",
keywords = "SETD2, Histone methyltransferase, Translation, Cell size",
author = "Molenaar, {Thom M.} and Muddassir Malik and Joana Silva and Liu, {Ning Qing} and Haarhuis, {Judith H. I.} and Christina Ambrosi and Kwesi-Maliepaard, {Eliza Mari} and Welsem, {Tibor van} and Tuncay Baubec and Faller, {William J.} and Leeuwen, {Fred van}",
note = "Funding Information: This work was supported by funding from The Dutch Research Council (Nederlandse Organisatie voor Wetenschappelijk Onderzoek; NWO-VICI-016.130.627 to F.v.L.), Dutch Cancer Society (KWF Kankerbestrijding; KWFNKI2018-1/11490 to F.v.L.), ZonMW (TOP91218022 to F.v.L.), EMBO (long-term fellowship ALTF 210-2018 to J.S.), and Swiss National Science Foundation (Schweizerischer Nationalfonds zur F{\"o}rderung der Wissenschaftlichen Forschung; 183722 to T.B.). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. Open Access funding provided by Antoni van Leeuwenhoek Nederlands Kanker Instituut. Deposited in PMC for immediate release. Funding Information: This work was supported by funding from The Dutch Research Council (Nederlandse Organisatie voor Wetenschappelijk Onderzoek; NWO-VICI-016.130.627 to F.v.L.), Dutch Cancer Society (KWF Kankerbestrijding; KWF-NKI2018-1/11490 to F.v.L.), ZonMW (TOP91218022 to F.v.L.), EMBO (long-term fellowship ALTF 210-2018 to J.S.), and Swiss National Science Foundation (Schweizerischer Nationalfonds zur F{\"o}rderung der Wissenschaftlichen Forschung; 183722 to T.B.). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. Open Access funding provided by Antoni van Leeuwenhoek Nederlands Kanker Instituut. Deposited in PMC for immediate release. Publisher Copyright: {\textcopyright} 2022 Company of Biologists Ltd. All rights reserved.",
year = "2022",
month = oct,
doi = "10.1242/jcs.259856",
language = "English",
volume = "135",
pages = "1--15",
journal = "Journal of Cell Science",
issn = "0021-9533",
publisher = "Company of Biologists Ltd",
number = "19",
}